• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Cure models, survival probabilities, and solid organ transplantation for patients with colorectal cancer.结直肠癌患者的治愈模型、生存概率与实体器官移植
Am J Transplant. 2025 Mar;25(3):545-555. doi: 10.1016/j.ajt.2024.08.018. Epub 2024 Sep 5.
2
Predicted Cure and Survival Among Transplant Recipients With a Previous Cancer Diagnosis.移植受者既往癌症诊断后的预测治愈率和生存情况。
J Clin Oncol. 2021 Dec 20;39(36):4039-4048. doi: 10.1200/JCO.21.01195. Epub 2021 Oct 22.
3
A 30-year analysis of colorectal adenocarcinoma in transplant recipients and proposal for altered screening.移植受者结直肠癌的30年分析及筛查方案的调整建议
J Gastrointest Surg. 2007 Mar;11(3):272-9. doi: 10.1007/s11605-007-0084-4.
4
Survival after a cancer diagnosis among solid organ transplant recipients in the United States.美国实体器官移植受者癌症诊断后的生存情况。
Cancer. 2019 Mar 15;125(6):933-942. doi: 10.1002/cncr.31782. Epub 2019 Jan 9.
5
Merging claims databases with a tumor registry to evaluate variations in cancer mortality: results from a pilot study of 698 colorectal cancer patients treated at one hospital in the 1990s.合并理赔数据库与肿瘤登记处以评估癌症死亡率的差异:对20世纪90年代在一家医院接受治疗的698名结直肠癌患者进行的一项试点研究结果。
Cancer Invest. 2004;22(2):225-33. doi: 10.1081/cnv-120030211.
6
Insurance Type and Solid Organ Transplantation Outcomes: A Historical Perspective on How Medicaid Expansion Might Impact Transplantation Outcomes.保险类型与实体器官移植结果:关于医疗补助扩大可能如何影响移植结果的历史视角
J Am Coll Surg. 2016 Oct;223(4):611-620.e4. doi: 10.1016/j.jamcollsurg.2016.07.004. Epub 2016 Jul 25.
7
Previous Solid Organ Transplantation Influences Both Cancer Treatment and Survival Among Colorectal Cancer Patients.先前的实体器官移植会影响结直肠癌患者的癌症治疗和生存。
Transpl Int. 2024 Sep 20;37:13173. doi: 10.3389/ti.2024.13173. eCollection 2024.
8
Solid Organ Transplantation and Survival among Individuals with a History of Cancer.实体器官移植与癌症病史个体的生存。
Cancer Epidemiol Biomarkers Prev. 2021 Jul;30(7):1312-1319. doi: 10.1158/1055-9965.EPI-21-0044. Epub 2021 Apr 29.
9
Outcomes in solid organ transplant recipients with a pretransplant diagnosis of melanoma.实体器官移植受者在移植前诊断为黑色素瘤的结果。
Am J Transplant. 2024 Jun;24(6):993-1002. doi: 10.1016/j.ajt.2024.02.013. Epub 2024 Feb 20.
10
Sebaceous Carcinoma Incidence and Survival Among Solid Organ Transplant Recipients in the United States, 1987-2017.美国 1987-2017 年实体器官移植受者的皮脂腺癌发病和生存情况。
JAMA Dermatol. 2020 Dec 1;156(12):1307-1314. doi: 10.1001/jamadermatol.2020.3111.

引用本文的文献

1
Application of flexible parametric cure model in determination of effective factors on the technique of survival peritoneal dialysis patients in adults of Iran.灵活参数治愈模型在确定影响伊朗成年腹膜透析患者生存技术的相关因素中的应用
PLoS One. 2025 Jul 22;20(7):e0326748. doi: 10.1371/journal.pone.0326748. eCollection 2025.
2
A new cure model accounting for longitudinal data and flexible patterns of hazard ratios over time.一种考虑纵向数据和随时间变化的灵活风险比模式的新治疗模型。
Stat Methods Med Res. 2025 Apr;34(4):683-700. doi: 10.1177/09622802251320793. Epub 2025 Feb 28.

本文引用的文献

1
Long-Term Survival, Prognostic Factors, and Selection of Patients With Colorectal Cancer for Liver Transplant: A Nonrandomized Controlled Trial.结直肠癌患者肝移植的长期生存、预后因素及患者选择:一项非随机对照试验。
JAMA Surg. 2023 Sep 1;158(9):e232932. doi: 10.1001/jamasurg.2023.2932. Epub 2023 Sep 13.
2
Mortality among solid organ transplant recipients with a pretransplant cancer diagnosis.实体器官移植受者移植前癌症诊断的死亡率。
Am J Transplant. 2023 Feb;23(2):257-264. doi: 10.1016/j.ajt.2022.11.006. Epub 2023 Jan 12.
3
Predicted Cure and Survival Among Transplant Recipients With a Previous Cancer Diagnosis.移植受者既往癌症诊断后的预测治愈率和生存情况。
J Clin Oncol. 2021 Dec 20;39(36):4039-4048. doi: 10.1200/JCO.21.01195. Epub 2021 Oct 22.
4
Liver transplantation for non-resectable colorectal liver metastases: the International Hepato-Pancreato-Biliary Association consensus guidelines.不可切除结直肠肝转移的肝移植:国际肝胆胰协会共识指南。
Lancet Gastroenterol Hepatol. 2021 Nov;6(11):933-946. doi: 10.1016/S2468-1253(21)00219-3. Epub 2021 Sep 8.
5
Cancer cure for 32 cancer types: results from the EUROCARE-5 study.32 种癌症的癌症治愈方法:来自 EUROCARE-5 研究的结果。
Int J Epidemiol. 2020 Oct 1;49(5):1517-1525. doi: 10.1093/ije/dyaa128.
6
Preexisting melanoma and hematological malignancies, prognosis, and timing to solid organ transplantation: A consensus expert opinion statement.原有黑色素瘤和血液系统恶性肿瘤、预后和实体器官移植时机:共识专家意见声明。
Am J Transplant. 2021 Feb;21(2):475-483. doi: 10.1111/ajt.16324. Epub 2020 Oct 10.
7
Pretransplant solid organ malignancy and organ transplant candidacy: A consensus expert opinion statement.移植前实体器官恶性肿瘤与器官移植候选资格:专家共识意见声明。
Am J Transplant. 2021 Feb;21(2):460-474. doi: 10.1111/ajt.16318. Epub 2020 Oct 23.
8
Organ allocation in the age of the algorithm: avoiding futile transplantation - utility in allocation.算法时代的器官分配:避免无效移植 - 分配中的效用。
Curr Opin Organ Transplant. 2020 Jun;25(3):305-309. doi: 10.1097/MOT.0000000000000752.
9
KDIGO Clinical Practice Guideline on the Evaluation and Management of Candidates for Kidney Transplantation.KDIGO 临床实践指南:肾移植候选人的评估和管理。
Transplantation. 2020 Apr;104(4S1 Suppl 1):S11-S103. doi: 10.1097/TP.0000000000003136.
10
Survival after a cancer diagnosis among solid organ transplant recipients in the United States.美国实体器官移植受者癌症诊断后的生存情况。
Cancer. 2019 Mar 15;125(6):933-942. doi: 10.1002/cncr.31782. Epub 2019 Jan 9.

结直肠癌患者的治愈模型、生存概率与实体器官移植

Cure models, survival probabilities, and solid organ transplantation for patients with colorectal cancer.

作者信息

Engels Eric A, Mandal Soutrik, Corley Douglas A, Blosser Christopher D, Hart Allyson, Lynch Charles F, Qiao Baozhen, Pawlish Karen S, Haber Gregory, Yu Kelly J, Pfeiffer Ruth M

机构信息

Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, USA.

Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, USA; Department of Population Health, New York University, New York, New York, USA.

出版信息

Am J Transplant. 2025 Mar;25(3):545-555. doi: 10.1016/j.ajt.2024.08.018. Epub 2024 Sep 5.

DOI:10.1016/j.ajt.2024.08.018
PMID:39182612
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11842210/
Abstract

A previous cancer diagnosis can preclude patients from consideration for solid organ transplantation. Statistical models may improve candidate selection. We fitted statistical cure models and estimated 5-year cancer-specific survival (5yCSS) for colorectal cancer patients in the United States using registry data. The median cure probability at cancer diagnosis for patients in the general population was 0.67. Among 956 colorectal cancer patients who underwent solid organ transplantation, the median time since diagnosis was 6.3 years and the median 5yCSS at transplantation was 0.96. Patients with a 5yCSS below 0.90 had increased posttransplant cancer-specific mortality (hazard ratio 3.31, 95% CI 1.52-7.21). Compared with recently published guidelines, our models suggested shorter wait times for some groups of colorectal cancer patients (eg, stage IIA cancers) and longer wait times for others (stages IIB, IIIB, IIIC, IV). In conclusion, colorectal cancer patients undergoing solid organ transplantation had excellent prognoses, reflecting selection incorporating existing guidelines and clinical judgment. Nonetheless, 5yCSS probabilities estimated from cure models offer additional prognostic information for patients considered for transplantation and identify situations where current guidelines might be revised. We developed a web-based tool for clinicians to calculate 5yCSS probabilities for use in transplant evaluation for individual colorectal cancer patients (https://dceg.cancer.gov/tools/risk-assessment/calculator-of-colorectal-cancer-survival-probability).

摘要

既往癌症诊断可能会使患者失去接受实体器官移植的机会。统计模型或许能改善候选者的选择。我们利用登记数据拟合了统计治愈模型,并估算了美国结直肠癌患者的5年癌症特异性生存率(5yCSS)。普通人群中患者在癌症诊断时的治愈概率中位数为0.67。在956例接受实体器官移植的结直肠癌患者中,自诊断以来的时间中位数为6.3年,移植时的5yCSS中位数为0.96。5yCSS低于0.90的患者移植后癌症特异性死亡率增加(风险比3.31,95%置信区间1.52 - 7.21)。与最近发布的指南相比,我们的模型显示某些结直肠癌患者组(如IIA期癌症)的等待时间较短,而其他组(IIB期、IIIB期、IIIC期、IV期)的等待时间较长。总之,接受实体器官移植的结直肠癌患者预后良好,这反映了结合现有指南和临床判断的筛选情况。尽管如此,从治愈模型估算的5yCSS概率为考虑移植的患者提供了额外的预后信息,并识别出可能需要修订当前指南的情况。我们为临床医生开发了一个基于网络的工具,用于计算5yCSS概率,以用于个体结直肠癌患者的移植评估(https://dceg.cancer.gov/tools/risk-assessment/calculator-of-colorectal-cancer-survival-probability)。